LETTER TO EDITOR
Year : 2022 | Volume
: 43 | Issue : 1 | Page : 89--90
The inconvenient corollaries of a convenient antiviral regime
Hitaishi Mehta1, Sunil Dogra1, Bhushan Kumar2,
1 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Dermatology, Shalby Hospital, SAS Nagar, Punjab, India
Dr. Bhushan Kumar
Shalby Hospital, SAS Nagar, Punjab
|How to cite this article:|
Mehta H, Dogra S, Kumar B. The inconvenient corollaries of a convenient antiviral regime.Indian J Sex Transm Dis 2022;43:89-90
|How to cite this URL:|
Mehta H, Dogra S, Kumar B. The inconvenient corollaries of a convenient antiviral regime. Indian J Sex Transm Dis [serial online] 2022 [cited 2022 Aug 18 ];43:89-90
Available from: https://www.ijstd.org/text.asp?2022/43/1/89/346585
We read with interest the article by Verma et al. entitled “Effectiveness and safety of oral acyclovir 1 g twice a day for 3 days in the management of genital herpes.” The authors evaluated a short course, higher dose acyclovir regimen with the rationale that such a regime would be more convenient and cheaper. While the assumption sounds appealing in theory, certain caveats must be considered.
The fundamental shortcoming of employing acyclovir in a twice-daily antiviral regimen is the short half-life of the drug (2–3 h). Further, the oral bioavailability of acyclovir is merely 15%–30% which further reduces with higher dosage. Any treatment regimen must be based on minimal inhibitory concentration levels of the drug and dosage schedules which can achieve this. The rationale of high dose, less frequent dosing is not justifiable for acyclovir. Most abbreviated regimens have employed longer-acting agents such as valaciclovir and famciclovir.,
The study recruited cases of clinically active genital herpes. Definitive diagnosis of genital herpes requires laboratory confirmation by viral culture, polymerase chain reaction, direct fluorescence antibody, and type-specific serologic tests. Not all of their patients had the diagnosis confirmed by the relevant laboratory tests. While the syndromic approach justifies clinical diagnosis and management of genital herpes, utilization of laboratory investigations for diagnostic precision is an essential requirement for clinical trials.
The primary goals of antiviral therapy in genital herpes are, reducing the duration of symptoms, early healing of lesions, and limiting viral shedding. In the present study, the duration of symptoms before presentation have not been mentioned, and healing time has been measured from the day of initiation of therapy. Healing time of 3 days in 40.9% of patients suggests a longer duration of disease at the time of recruitment. Effective management of recurrent genital herpes requires initiation of therapy at the earliest, preferably within 1 day of appearance of lesions, therapy is not indicated in patients with a longer duration of symptoms unless the disease is extensive or severely symptomatic. As the duration of episode of untreated recurrent herpes varies from 5 to 10 days, the current regimen (with average healing time of 4.9 days) may not have any added benefit over placebo. As far as primary genital herpes is concerned, it is not justified to treat such patients with 3 days of therapy in view of the severe nature of disease, associated viremia, and possible systemic complications; such patients must be treated for 7–10 days with adequate antiviral dosages.
Finally, an evidence-based regimen of acyclovir 800 mg thrice a day for two days is already available as recommended by European guidelines for recurrent herpes, and it is more economical and shorter than the proposed regimen with equal pill burden. Hence, this new treatment schedule does not seem to have any added benefits over the current guidelines for recurrent genital herpes. Due to the lack of sufficient evidence, purpose and logic behind this new schedule, it would be prudent for clinicians to adhere to the regimens recommended in the WHO/CDC/European guidelines.,
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
|1||Verma K, Sonune M, Dar L, Bhari N, Jangid B. Effectiveness and safety of oral acyclovir 1 g twice a day for 3 days in the management of genital herpes. Indian J Sex Transm Dis AIDS 2021;42:46-9.|
|2||Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 1983;8:187-201.|
|3||Modi S, Van L, Gewirtzman A, Mendoza N, Bartlett B, Tremaine AM, et al. Single-day treatment for orolabial and genital herpes: A brief review of pathogenesis and pharmacology. Ther Clin Risk Manag 2008;4:409-17.|
|4||Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64:1-137.|
|5||Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944-8.|
|6||Patel R, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S, et al. 2017 European guidelines for the management of genital herpes. Int J STD AIDS 2017;28:1366-79.|